Full Disclosure: Toward a Participatory and Risk-Limiting Approach to Neuroleptic Drugs

ISSN： 1559-4343

Source： Ethical Human Psychology and Psychiatry, Vol.9, Iss.1, 2007-03, pp. : 35-61

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Postpartum Period: A Risk Factor for Neuroleptic Malignant Syndrome

By Fido A.A.

Annals of Clinical Psychiatry (after Jan 1, 2004), Vol. 11, Iss. 1, 1999-03 ,pp. : 13-15

Springer Publishing Company

Access to resources Recommend Favorite

Neuroleptic-induced dystonia: incidence and risk factors

By Ballerini M. Bellini S. Niccolai C. Pieroni V. Ferrara M.

European Psychiatry, Vol. 17, Iss. 6, 2002-10 ,pp. : 366-368

Elsevier

Access to resources Recommend Favorite

Atypical Neuroleptic Drugs Downregulate Dopamine Sensitivity in Rat Cortical and Striatal Astrocytes

By Reuss B. Unsicker K.

Molecular and Cellular Neuroscience, Vol. 18, Iss. 2, 2001-08 ,pp. : 197-209

Academic Press

Access to resources Recommend Favorite

Blocking of Cloned Low-Threshold Ca²⁺ Channels by Neuroleptic Drugs

By Osipenko V.N. Naidenov V.G. Kostyuk P.G. Shuba Y.M.

Neurophysiology, Vol. 35, Iss. 1, 2003-01 ,pp. : 7-16

Springer Publishing Company

Access to resources Recommend Favorite

Culture and attitudes toward psychological help-seeking influence clients’ self-disclosure

By Helmes Edward Gallou Laura

European Journal of Psychotherapy, Counselling & Health, Vol. 16, Iss. 2, 2014-04 ,pp. : 163-176

Routledge Ltd

Access to resources Recommend Favorite